Australia markets open in 8 hours 21 minutes

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.90+1.10 (+2.98%)
As of 09:38AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.41B
Enterprise value 1.89B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.79
Enterprise value/revenue 10.87k
Enterprise value/EBITDA -9.62

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-5.23%
S&P500 52-week change 314.90%
52-week high 343.75
52-week low 327.99
50-day moving average 332.96
200-day moving average 336.88

Share statistics

Avg vol (3-month) 3578.01k
Avg vol (10-day) 31.06M
Shares outstanding 565.43M
Implied shares outstanding 665.43M
Float 860.89M
% held by insiders 10.65%
% held by institutions 194.60%
Shares short (14 Nov 2023) 41.71M
Short ratio (14 Nov 2023) 42.88
Short % of float (14 Nov 2023) 42.63%
Short % of shares outstanding (14 Nov 2023) 42.62%
Shares short (prior month 12 Oct 2023) 41.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-17.60%
Return on equity (ttm)-25.19%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-96.33M
EBITDA -200.48M
Net income avi to common (ttm)-175.46M
Diluted EPS (ttm)-2.66
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)526.67M
Total cash per share (mrq)8.05
Total debt (mrq)11M
Total debt/equity (mrq)1.73%
Current ratio (mrq)21.46
Book value per share (mrq)9.79

Cash flow statement

Operating cash flow (ttm)-142.59M
Levered free cash flow (ttm)-87.77M